Arrowhead Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2026 Annual Meeting of Stockholders held on March 19, 2026. The filing covers the submission of matters to a vote of security holders, including director elections, executive compensation, an incentive plan, and auditor ratification.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
As of the record date (January 22, 2026), the Company had 140,010,690 shares outstanding. At the meeting, 119,801,542 shares were present or represented by proxy. Three of the four proposals passed; the Say-on-Pay proposal failed.
- Election of Directors: All seven nominees were elected. Notable dissent included Michael Perr (31,342,814 votes against) and Hongbo L (8,971,012 votes against).
- Say-on-Pay Proposal: Failed. Votes were 41,625,740 FOR and 59,963,903 AGAINST.
- 2021 Incentive Plan: Approved with 99,158,276 votes FOR.
- Auditor Ratification: KPMG LLP was ratified with 119,053,168 votes FOR.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary, risks, contingencies, or unusual items beyond the voting results.
Investor Verification Checklist
- Verify the reasons for the significant "Against" votes on the Say-on-Pay proposal and specific director nominees (Michael Perr, Hongbo L, William Waddill).
- Review the Company's subsequent response to the failed Say-on-Pay vote.
- Confirm the terms of the newly approved Amended and Restated 2021 Incentive Plan.
- Check for any related press releases or 10-K filings for the fiscal year ending September 30, 2026, to obtain financial performance data not included in this 8-K.